Bernard Ravina

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
    Mov Disord 22:1061-8. 2007
  2. doi A longitudinal program for biomarker development in Parkinson's disease: a feasibility study
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 24:2081-90. 2009
  3. pmc The impact of depressive symptoms in early Parkinson disease
    B Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Neurology 69:342-7. 2007
  4. doi The relationship between CAG repeat length and clinical progression in Huntington's disease
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 23:1223-7. 2008
  5. pmc Local institutional review board (IRB) review of a multicenter trial: local costs without local context
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Ann Neurol 67:258-60. 2010
  6. pmc The course of depressive symptoms in early Parkinson's disease
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, New York, USA
    Mov Disord 24:1306-11. 2009
  7. pmc Long term understanding of study information in research participants with Parkinson's disease
    Bernard Ravina
    University of Rochester, School of Medicine and Dentistry, Department of Neurology, Rochester, NY 14610, USA
    Parkinsonism Relat Disord 16:60-3. 2010
  8. ncbi A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit
    M Flint Beal
    Department of Neurology, Weill Cornell Medical College, New York Hospital, New York
    JAMA Neurol 71:543-52. 2014
  9. pmc Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
    Rodger J Elble
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
    Mov Disord 25:1082-6. 2010
  10. ncbi A randomized, placebo-controlled trial of latrepirdine in Huntington disease
    Karl Kieburtz
    Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA
    Arch Neurol 67:154-60. 2010

Research Grants

Detail Information

Publications30

  1. ncbi Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
    Mov Disord 22:1061-8. 2007
    ..These criteria require validation and may be refined, but form a starting point for studies of the epidemiology and pathophysiology of PDPsy, and are a potential indication for therapy development...
  2. doi A longitudinal program for biomarker development in Parkinson's disease: a feasibility study
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 24:2081-90. 2009
    ..The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data...
  3. pmc The impact of depressive symptoms in early Parkinson disease
    B Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Neurology 69:342-7. 2007
    ..No previous study has systematically examined the impact of depressive symptoms in early, untreated PD...
  4. doi The relationship between CAG repeat length and clinical progression in Huntington's disease
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 23:1223-7. 2008
    ..This finding may account for the variable results from previous studies examining CAGn and progression. Adjusting for CAGn may be important for clinical trials...
  5. pmc Local institutional review board (IRB) review of a multicenter trial: local costs without local context
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Ann Neurol 67:258-60. 2010
    ..This may be an opportune time for the National Institute of Neurological Disorders and Stroke (NINDS) to adopt a central review model...
  6. pmc The course of depressive symptoms in early Parkinson's disease
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, New York, USA
    Mov Disord 24:1306-11. 2009
    ..83-0.92). Mild depressive symptoms have a variable course, with remission and development of more sustained and severe symptoms occurring over time. More severe depressive symptoms may herald a protracted course...
  7. pmc Long term understanding of study information in research participants with Parkinson's disease
    Bernard Ravina
    University of Rochester, School of Medicine and Dentistry, Department of Neurology, Rochester, NY 14610, USA
    Parkinsonism Relat Disord 16:60-3. 2010
    ..Little is known about research participants' understanding of consent information over the course of a clinical study and the relationship of this information with participant behavior...
  8. ncbi A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit
    M Flint Beal
    Department of Neurology, Weill Cornell Medical College, New York Hospital, New York
    JAMA Neurol 71:543-52. 2014
    ..A previous phase II study suggested possible clinical benefit...
  9. pmc Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
    Rodger J Elble
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
    Mov Disord 25:1082-6. 2010
    ..We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment...
  10. ncbi A randomized, placebo-controlled trial of latrepirdine in Huntington disease
    Karl Kieburtz
    Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA
    Arch Neurol 67:154-60. 2010
    ..To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms...
  11. doi Analysis of the visual system in Friedreich ataxia
    Lauren A Seyer
    Department of Neurology, University of Pennsylvania Medical School, Philadelphia, PA, USA
    J Neurol 260:2362-9. 2013
    ..This suggests that such measures are useful markers of neurologic progression in FRDA...
  12. ncbi Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis
    Tiffini Voss
    University of Virginia, Department of Neurology, PO Box 800394, Charlottesville, VA, USA
    Parkinsonism Relat Disord 19:295-9. 2013
    ..Parkinson's disease psychosis is a frequent and serious complication of advanced disease, but few disease-specific outcome measures exist...
  13. pmc Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participants
    Sean R Regner
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Child Neurol 27:1152-8. 2012
    ..However, modeling of disease progression identified substantial ceiling effects in the Friedreich Ataxia Rating Scale, suggesting this measure is most useful in subjects before maximal deficit is approached...
  14. ncbi A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone)
    Radu Constantinescu
    Department of Neurology, Clinical Trials Coordination Center, University of Rochester Medical Center, Rochester, New York, USA
    J Clin Pharmacol 47:1580-6. 2007
  15. doi The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease
    David J Gill
    Department of Neurology, University of Rochester, Rochester, NY, USA
    Mov Disord 23:1043-6. 2008
    ..81. The correlation coefficient between the MoCA and a neuropsychologic battery was 0.72. The MoCA is reliable and valid in the PD population and warrants further study as a screening tool for cognitive dysfunction...
  16. ncbi Why hasn't neuroprotection worked in Parkinson's disease?
    Karl Kieburtz
    University of Rochester Medical Center, Rochester, NY, USA
    Nat Clin Pract Neurol 3:240-1. 2007
  17. doi Mortality in Friedreich ataxia
    Amy Y Tsou
    Department of Neurology, University of Pennsylvania Medical School, USA
    J Neurol Sci 307:46-9. 2011
    ..Although cardiac dysfunction is widely accepted as the most common cause of mortality in Friedreich ataxia (FRDA), no studies have evaluated this since the advent of specific clinical and genetic diagnostic criteria...
  18. ncbi Neuroprotection in Parkinson's disease: an elusive goal
    Kevin M Biglan
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14620, USA
    Semin Neurol 27:106-12. 2007
    ..Ultimately, overcoming the unique challenges of a heterogenous, slowly progressive disorder with multiple potential outcome measures will be necessary to identify treatments that have meaningful effects...
  19. ncbi Neuroprotection in Parkinson's disease: myth or reality?
    Tiffini Voss
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Movement and Inherited Neurological Disorders Unit, Rochester, NY 14620, USA
    Curr Neurol Neurosci Rep 8:304-9. 2008
    ..It is hoped that ongoing work in this field will lead to treatments that delay the progression of PD...
  20. pmc Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease
    David K Simon
    Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    BMC Med Genet 11:53. 2010
    ..We investigated the potential contribution of mtDNA variants or mutations to the risk of PD...
  21. ncbi Preference-based quality-of-life in patients with Parkinson's disease
    Andrew Siderowf
    Departments of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
    Neurology 59:103-8. 2002
    ..Because of this property, they are the appropriate measures of quality of life for cost-effectiveness analysis. Although preference-based scales are widely used, their validity has rarely been tested in specific patient groups...
  22. ncbi Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group
    Laura Marsh
    Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Mov Disord 21:148-58. 2006
    ..The proposed diagnostic criteria are provisional and intended to be defined further and validated but provide a common starting point for clinical research in PD-associated depression...
  23. ncbi Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safety
    Tanya Simuni
    Parkinson s Disease and Movement Disorders Center, Pennsylvania Hospital, Philadelphia, USA
    J Neurosurg 96:666-72. 2002
    ..The present study was designed to investigate the safety and efficacy of bilateral stimulation of the STN for the treatment of PD...
  24. ncbi From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials
    Jill Heemskerk
    Technology Development Program, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland 20892, USA
    Nat Neurosci 5:1027-9. 2002
  25. ncbi Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation
    Stephen Hague
    Molecular Genetics Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
    Ann Neurol 54:271-4. 2003
    ..This subject was diagnosed with probable PD at age 24 years with asymmetric onset and an excellent response to levodopa therapy. Our observations suggest that sequence alterations in DJ-1 are a rare cause of early-onset PD...
  26. ncbi Exercise-induced dystonia as a preceding symptom of familial Parkinson's disease
    Michiko K Bruno
    Parkinson s Unit, Division of Neurogenetics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Mov Disord 19:228-30. 2004
    ..Further genotype-phenotype studies in this and similar families may give clues to pre-symptomatic symptoms in PD and may reflect a particular phenotype of interest for genetics studies in the future...
  27. ncbi A responsive outcome for Parkinson's disease neuroprotection futility studies
    Jordan J Elm
    Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, SC 29425, USA
    Ann Neurol 57:197-203. 2005
    ....
  28. pmc Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease
    Masahiro Fujita
    Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 1, Room B3 10, I Center Drive, MSC 0135, Bethesda, MD, USA
    Ann Neurol 59:174-7. 2006
    ..Nicotinic acetylcholine receptors have close interactions with the dopaminergic system and play critical roles in cognitive function. The purpose of this study was to compare these receptors between living PD patients and healthy subjects...
  29. ncbi Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials
    Paulo Guimaraes
    Dept of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, 135 Cannon St Suite 303, Charleston, SC 29425, USA
    Clin Trials 2:509-18. 2005
    ..Models can help better understand behavior of the UPDRS after initiation of symptomatic therapy when scores will improve and eventually start deteriorating again...
  30. ncbi Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease
    Mary E Putt
    Department of Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, 621 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
    Control Clin Trials 23:111-26. 2002
    ..4 months, respectively, a substantial saving over either parallel group design. The cost of allowing for carryover in the sample size calculation is about 1.2 months of study time...

Research Grants1

  1. Creatine Safety and Efficacy in HD: Coordination and Statistical Center
    Bernard Ravina; Fiscal Year: 2007
    ..This will allow NCCAM to distribute authoritative information to the public about the safety of creatine. ..